Article in The Journal of physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Abul FajolSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-3202-5697
Kylie HeitmanSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
S Madison ThomasSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Qing LiSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0003-4540-7915
Tanecia MitchellDepartment of Urology, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-4032-913X
Jorge GamboaSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-4204-7670
Abolfazl ZarjouSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-8676-847X
Orlando M GutierrezSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Christian FaulSection of Mineral Metabolism, Division of Nephrology, Department of Medicine, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0002-7512-0977
Funding
Changes in phosphate metabolism cause pathologic cardiac remodeling in chronic kidney disease (CKD)R01HL145528 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI FAUL, CHRISTIAN, WHITE, KENNETH E · 2019 to 2022
$2.4M
Regulation of Macrophage Phenotype by Ferritin Heavy Chain in CKDR01DK134402 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Abolfazl Zarjou · 2023 to 2026
$1.6M
Hyperphosphatemia Contributes to Systemic Inflammation and Anemia in Chronic Kidney DiseaseR01DK125459 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAUL, CHRISTIAN · 2020 to 2023
$1.5M
Hyperphosphatemia Contributes to Skeletal Muscle Atrophy in the Absence and Presence of Chronic Kidney DiseaseF31DK131914 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HEITMAN, KYLIE · 2022 to 2024
$143k
American Heart Association (AHA) 24PRE1242192American Heart Association-American Stroke Association AHA_24PRE1242192HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R01HL145528HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) F31DK13191HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R01DK125459NHLBI NIH HHS R01 HL145528NIDDK NIH HHS F31 DK131914NIDDK NIH HHS R01 DK125459NIDDK NIH HHS R01 DK134402
6 · The paper itself
Abstract
High serum levels of phosphate (hyperphosphatemia) can target vascular smooth muscle cells (VSMC) and induce calcium-phosphate precipitations and vascular calcification, thereby contributing to high cardiovascular mortality rates in chronic kidney disease (CKD). Calcifications within soft tissues beyond the vasculature are not well described, and the involvement of cell types other than VSMCs is not clear. Here, we studied extravascular calcifications in various soft tissues from mouse models with hyperphosphatemia. We found that klotho-deficient (kl/kl) mice without CKD not only developed calcifications in the aorta, but also in the kidney and stomach, which was accompanied by significant elevations in tissue content of phosphate. Administration of a magnesium-rich diet, which blocks the formation of calcium-phosphate crystals, prevented calcifications in these tissues. Liver, heart, skeletal muscle, spleen, brain and skin showed no signs of calcifications. Similarly, CKD mice with global deletion of Col4a3 (Col4a3
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Soft tissue accumulations of phosphate are not always associated with serum phosphate or with calcifications in mouse models of hyperphosphatemia. · full record | OpenQuestion